Invention Grant
- Patent Title: 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
-
Application No.: US16415803Application Date: 2019-05-17
-
Publication No.: US11358955B2Publication Date: 2022-06-14
- Inventor: Sui Xiong Cai , Ye Edward Tian , Haijun Dong , Qingbing Xu , Lizhen Wu , Lijun Liu , Yangzhen Jiang , Qingli Bao , Guoxiang Wang , Feng Yin , Chengyun Gu , Xiuhua Hu , Xiaozhu Wang , Sishun Kang , Shengzhi Chen
- Applicant: IMPACT Therapeutics, Inc.
- Applicant Address: CN Jiangsu
- Assignee: IMPACT Therapeutics, Inc.
- Current Assignee: IMPACT Therapeutics, Inc.
- Current Assignee Address: CN Jiangsu
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: CN201110082475.6 20110401,WOPCT/CN2011/077034 20110711
- Main IPC: C07D409/12
- IPC: C07D409/12 ; A61K31/517 ; C07D401/06 ; C07D239/96 ; A61K45/06 ; C07D401/12 ; C07D403/12 ; C07D405/12 ; C07D413/12 ; C07D417/12 ; C07D471/04 ; C07D487/04
Abstract:
Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
Public/Granted literature
- US20190270732A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof Public/Granted day:2019-09-05
Information query
